Quotient CEO Paul Cowan spoke with Outsourcing-pharma at this year's AAPS in Los Angeles, US, explaining that, though a number of recent acquisitions, the firm has created a single source drug development offering with reduced timelines and costs.
Cowan went on to say that historically, early-stage regulatory development often meant working with a number of specialist service providers, adding an extra layer of complexity to the already challenging process.
"Now, [through the new service] clients have a single point of contact to undertake that full metabolism package, from the manufacture of radio-synthesised product through to human clinical dosing."
He added that Quotient will offer "synthesis-to-clinic" to pharma and biotech firms and predicted that industry desire to conduct human metabolism assessment earlier in the development process, as well as growing regulatory recognition for Phase 0 microdosing and microtracer studies, will be key drivers for demand.
Cowan also stressed that the integrated nature of Quotient's offering means the firm can adjust clinical development time lines when necessary, which he predicted will help clients avoid cancellations fees and reduce the cost of the overall process.
